King of Prussia, Pennsylvania — January 20, 2026 — Leads & Copy — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has announced positive pathology results and safety outcomes from its Phase 1b dose escalation clinical trial of PH-762 for skin cancer treatment.
The trial, which included 22 patients with cutaneous carcinomas, showed a 70% overall response rate for squamous cell carcinomas. Notably, 10 out of 14 responders experienced 100% clearance of the treated lesional site.
According to the company, the data also indicated favorable safety and tolerability across all dose escalations.
Of the 20 patients with cutaneous squamous cell carcinoma (cSCC), 14 were determined to be pathologic responders. Ten patients had complete responses (100% clearance), two had major/near clear responses (greater than 90% clearance), and two had partial responses (greater than 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response (greater than 50% clearance). Six cSCC patients and one melanoma patient had responses of less than 50%, with no disease progression observed.
The company reported no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects. PH-762 was well tolerated by all enrolled patients across the five dose-escalating cohorts, with a 20-fold increase in drug concentration from the first to the final cohort. Extended follow-up safety data is expected in the second quarter of 2026.
Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals, stated that the pathology data, with a 70% overall response rate and favorable safety data, is remarkable. Bitterman added that the company is actively beginning the design of a follow-on clinical trial.
The Phase 1b trial was designed to evaluate the safety and tolerability of intratumoral PH-762 in Stages 1, 2, and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Patients received four weekly injections of PH-762, with pathologic response assessed two weeks after the final injection.
Phio Pharmaceuticals Corp. is focused on immuno-oncology therapeutics using its INTASYL® gene silencing technology. The company’s lead clinical program, PH-762, targets the PD-1 gene in skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma as a potential non-surgical treatment.
Contact:
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Source: Phio Pharmaceuticals Corp.